This milestone marks Respiratorius’ first granted formulation patent, protecting a unique method for administering valproate as a pre‑treatment in oncology. The patent carries a priority date of April 21, 2016, and once formally granted, will confer market exclusivity for at least 20 years from that date. Corresponding patents have already been approved in Japan, Canada and the United States.

“It is extremely satisfying to see our formulation patent advance to allowance in Europe,” says Johan Drott, CEO of Respiratorius. “With patent protection secured in all key markets—including the US, our single most important and valuable market for VAL001—we anticipate increased industry and investor interest as we progress VAL001 toward clinical development.”

About VAL001

VAL001 is an innovative oral formulation of sodium valproate designed to enhance tolerability and efficacy when administered prior to standard cancer therapy. Preclinical data suggest that VAL001 may sensitize tumour cells to chemotherapy, potentially improving patient outcomes across multiple indications.

For further information, please contact:

This disclosure contains information that Respiratorius is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 27-05-2025 14:33 CET.